jRCT2080221174未知N/a
GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma
GlaxoSmithKline K.K.0 个研究点开始时间: 待定
适应症
试验速览
- 阶段
- N/a
- 发起方
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Refer to 'GSK Clinical Study Register'
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •Refer to 'GSK Clinical Study Register'
排除标准
- •Refer to 'GSK Clinical Study Register'
结局指标
主要结局
-
Refer to 'GSK Clinical Study Register' Refer to 'GSK Clinical Study Register'
次要结局
未报告次要终点
研究者
相似试验
未知
Unknown
GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanomamelanomaJPRN-jRCT2080221174GlaxoSmithKline K.K.
进行中（未招募）
3 期
Resected Stage III Melanoma With Macroscopic InvolvementACTRN12609000099224GlaxoSmithKline Biologicals1,300
未知
3 期
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Canceron-Small Cell Lung CancerJPRN-jRCT2080220584GlaxoSmithKline K.K.
已完成
2 期
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced MelanomaMelanomaNCT00942162GlaxoSmithKline125
终止
3 期
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their TumorMelanomaNCT00796445GlaxoSmithKline1,351